| 51.39 Real-Time Quote | -0.10 / -0.19%Today’s Change | 40.86 Today|||52-Week Range 53.45 | +8.72% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $64.5B |
Company Description
AstraZeneca Plc is a global research-based biopharmaceutical company, which primarily focuses on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. The company sells products under the brands Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on April 6, 1999 and is headquartered in London, the United Kingdom.
Employees

Shareholders
| Other institutional | 5.55% |
| Mutual fund holders | 3.83% |
| Individual stakeholders | -- |
Top Executives
| Pascal Soriot, PhD, MBA | Chief Executive Officer & Executive Director |
| David Smith | EVP-Global Operations & Information Services |
| Simon Lowth, MBA | Chief Financial Officer & Executive Director |
| Briggs Morrison, MD, PhD | Chief Medical Officer |
| Edward Bradley | Senior VP & Head-Innovative Medicines Oncology |